Inventor
Peter Sieger
Inventor
Mittelbiberach, DE
Overview
Patents· 38 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds38%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations31%
A61KPreparations for medical, dental or toiletry purposes23%
C07BGeneral methods of organic chemistry5%
C07CAcyclic or carbocyclic compounds3%
PatentTitleYear
11,084,819Polymorphs202110,301,313Polymorphs20199,815,837'Polymorphs'20179,493,462'Polymorphs'20169,309,228'Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as a medicament and the preparation thereof'20169,266,888'Polymorphs'20169,212,183'Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine'20158,906,931'9-[4-(3-chloro-2-fluoro-phenylamino-7-methoxy-quinazoline-6-yloxy]-1,4-diaza-spiro[5.5]undecane-5-one dimaleate, use thereof as a medicament and method for the production thereof'20148,865,729'Salt forms of a xanthine compound'20148,853,225'9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy-quinazoline-6-yloxy]-1,4-diaza-spiro[5.5] undecane-5-one dimaleate, use thereof as a medicament and method for the production thereof'20148,686,148'Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof'20148,664,222'Specific salt, anhydrous and crystalline form of a dihydropteridione derivative'20148,637,530'8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals'20148,426,586'Process for preparing amino crotonyl compounds'20138,329,695'Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide'20128,202,867'Methods of using hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide'20128,188,086'Specific salt, anhydrous and crystalline form of a dihydropteridione derivative'20128,106,060'8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals'20128,034,816'Hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament'20118,034,809'Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments'20117,968,717'Crystalline anhydrate with anticholinergic efficacy'20117,939,658'Enantiomeric pure beta agonists, manufacturing and use as a medicaments thereof'20117,932,273'3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament'20117,728,134'Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament'20107,709,474'Enantiomerically pure beta agonists, manufacturing and use thereof'20107,534,789'Enantiomeric pure β agonists, manufacturing and use as a medicament thereof'20097,514,468'Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions'20097,491,719'Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments'20097,439,358'Specific salt, anhydrous and crystalline form of a dihydropteridione derivative'20087,294,721'(R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1(pyrrolidinocarbonyl)-ethyl]-benzimidazole, the monohydrochloride thereof, preparation thereof and the use as pharmaceutical composition'20077,220,742'Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments'20077,169,934'(R) 2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1 (pyrrolidinocarbonyl)-ethyl]-benzimidazole, the monohydrochloride thereof, preparation thereof and the use as pharmaceutical composition'20077,119,093'3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition'20066,908,928'Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions'20056,869,948'Meloxicam for oral administration'20056,777,423'Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions'20046,730,678'Benzoylguanidine salt and hydrates thereof'20046,608,055'Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition'2003Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2003–2009Patents assigned to BOEHRINGER INGELHEIM PHARMA (8)· patent assignee history
2003–2021Based in Mittelbiberach, DE· patent location history
2007–2021Patents assigned to BOEHRINGER INGELHEIM INT (29)· patent assignee history
2011–2012Based in Mittlebiberach, DE· patent location history
2012–2016Patents assigned to SIEGER PETER (14)· patent assignee history
2012–2015Patents assigned to PFRENGLE WALDEMAR (6)· patent assignee history
2012–2014Patents assigned to LINZ GUENTER (4)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| BOEHRINGER INGELHEIM INT | 29 | 2007–2021 |
| SIEGER PETERself | 14 | 2012–2016 |
| BOEHRINGER INGELHEIM PHARMA | 8 | 2003–2009 |
| PFRENGLE WALDEMAR | 6 | 2012–2015 |
| LINZ GUENTER | 4 | 2012–2014 |
Locations
| Location | Patents | Span |
|---|---|---|
| Mittelbiberach, DE | 36 | 2003–2021 |
| Mittlebiberach, DE | 2 | 2011–2012 |